X

Trial Profile

A pivotal trial of ANAVEX®2-73 (blarcamesine) in Parkinson's disease dementia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 16 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blarcamesine (Primary)
Indications Dementia; Parkinson's disease
Focus Registrational; Therapeutic Use
Sponsors Anavex Life Sciences

Most Recent Events

10 May 2022 According to an Anavex Life Sciences media release, the company expect to meet with FDA for discussing this study in 2022.
20 Oct 2020 New trial record
15 Oct 2020 According to an Anavex Life Sciences media release, the company is planning a pivotal trial of ANAVEX2-73 (blarcamesine) in Parkinson's disease dementia after submitting the results of the ANAVEX2-73-PDD-001 study to the FDA to obtain regulatory guidance.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com